Skip to main content

Integrated Biosimilar Atezolizumab Strategy

Translating biotech into accessible treatment.

1st Winner - Pharmaceutical Industrial Case Study

Problem

Biosimilar manufacturing requires cost efficiency. Cancer immunotherapy access varies globally. Indonesia's JKN system needs sustainable treatment strategies.

Overview

This industrial case study integrates continuous bioprocessing optimization, regulatory comparability frameworks, PD-L1 patient stratification, and JKN market-access strategy for biosimilar atezolizumab in NSCLC treatment.

Concept

A comprehensive industrial strategy optimizing biosimilar production through continuous bioprocessing while addressing patient stratification and healthcare system integration.

Scope

Biosimilar manufacturing strategy, continuous bioprocess optimization, regulatory comparability framework, PD-L1 patient stratification, cost-efficiency analysis, market-access strategy, and JKN integration.

Contribution

Developed collaboratively as part of a multidisciplinary team focused on pharmaceutical industrial innovation.

Reflection

This case highlighted how pharmaceutical strategy bridges scientific excellence, manufacturing efficiency, and equitable healthcare access.

Biosimilar StrategyBioprocessingHealthcare Access